GlobeNewsWire
22 Jul 2026, 10:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Pharvaris (PHVS) is developing novel, oral bradykinin B2 receptor antagonists for hereditary and acquired angioedema. — The development of oral alternatives to injectables for these conditions represents a potential significant shift in standard of care and market share.
+0.40A newly published review in Clinical Reviews in Allergy & Immunology validates B2 receptor antagonism as a therapeutic strategy for bradykinin-mediated diseases. — Peer-reviewed validation reduces scientific risk for the company's primary drug mechanism, though it is a review of existing evidence rather than new clinical trial data.
+0.20Research suggests bradykinin B2 receptor antagonism may be applicable to a broader range of conditions, including asthma, chronic cough, and allergic rhinitis. — Expanding the potential total addressable market (TAM) beyond angioedema provides long-term upside, but these are speculative future applications.
+0.10Continue reading
6 related stories
Search tags
Which stocks this story touches
The company is promoting the publication of a comprehensive review supporting the therapeutic target of its lead drug candidates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
